决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
100.0分
★★★★★
站内排序·非疗效
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
乳腺癌细胞治疗的现状
英文原题：Current State of Cell Therapies for Breast Cancer.
查看英文原题
Current State of Cell Therapies for Breast Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
转移性乳腺癌（BC）是一种侵袭性癌症，治疗难度极大。本综述讨论了转移性BC可用的标准治疗。进一步强调了在BC中靶向致癌驱动因子、肿瘤相关抗原和新抗原的理论依据。在解释免疫应答在成功免疫治疗研究中的重要性时，本综述提请注意过继性细胞疗法如何能够成为一种有用的免疫治疗工具。我们聚焦于BC中的过继性细胞疗法，涵盖TIL（肿瘤浸润淋巴细胞）疗法、工程化T细胞受体疗法、嵌合抗原受体疗法、树突状细胞疗法和NK 细胞疗法。在本研究中，我们旨在提供关于细胞免疫疗法用于BC的临床数据概述。最终，我们通过提出可用于治愈BC的未来过继性细胞疗法方法作为结论。
展开英文摘要原文
Metastatic breast cancer (BC) is an aggressive form of cancer and is an absolute challenge to treat. This review discusses the standard treatments available for metastatic BC. It further highlights the rationale for targeting oncodrivers, tumor-associated antigens, and neoantigens in BC. Explaining the significance of immune response in successful immunotherapeutic studies, it draws attention towards how adoptive cell therapy can be a useful immunotherapeutic tool.
We focus on adoptive cell therapy in BC covering tumor-infiltrating lymphocyte therapy, engineered T cell receptor therapy, chimeric antigen receptor therapy, dendritic cell therapy and natural killer cell therapy. In this work, we aim to provide an overview of clinical data regarding the use of cellular immunotherapies in BC. Eventually, we conclude by proposing future adoptive cell therapy approaches, which can be used to cure BC.
论文信息
- 作者
- Gautam N、Elleson KM、Ramamoorthi G、Czerniecki BJ
- 第一作者单位
- From the Clinical Science Division.
- 通讯作者单位
- Department of Breast Surgery, H. Lee Moffitt Cancer Center, Tampa, FL.United States
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Cancer journal (Sudbury, Mass.)2022 Jul-Aug 01
- 原文标识
- PubMed 35880940 · DOI 10.1097/PPO.0000000000000607